鲁索替尼治疗对传统疗法和脾切除术耐药的原发性骨髓纤维化患者：一例报告
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
作者信息
Aylı Meltem, Özcan Muhit, Cengiz Seval Güldane
机构信息
Ufuk University Faculty of Medicine, Department of Hematology, Ankara, Turkey E-mail:
出版信息
Turk J Haematol. 2015 Jun;32(2):180-3. doi: 10.4274/tjh.2013.0338.
Abstract
A 67-year-old male patient who was diagnosed with primary myelofibrosis 4 years ago did not respond to conventional therapies. The splenomegaly progressively increased, which caused spleen infarctions and led to the decision to perform a splenectomy procedure. After splenectomy, the patient started treatment with ruxolitinib. In the first month of ruxolitinib treatment, the patient became transfusion-free and all constitutional symptoms disappeared. However, in the sixth month of ruxolitinib treatment, the disease transformed to acute myeloblastic leukemia, and the patient died 1 month later. This is the first case report that shows the effects of ruxolitinib in a splenectomized patient.
摘要
一名67岁男性患者，4年前被诊断为原发性骨髓纤维化，对传统治疗无反应。脾肿大逐渐加重，导致脾梗死，因此决定进行脾切除术。脾切除术后，患者开始使用鲁索替尼治疗。在鲁索替尼治疗的第一个月，患者不再需要输血，所有全身症状均消失。然而，在鲁索替尼治疗的第六个月，疾病转变为急性髓细胞白血病，患者1个月后死亡。这是首例显示鲁索替尼对脾切除患者疗效的病例报告。
相似文献
1
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.鲁索替尼治疗对传统疗法和脾切除术耐药的原发性骨髓纤维化患者：一例报告
Turk J Haematol. 2015 Jun;32(2):180-3. doi: 10.4274/tjh.2013.0338.
2
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.芦可替尼与最佳可用疗法治疗骨髓纤维化的 JAK 抑制作用比较。
N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.
3
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.JUMP 研究的主要分析结果，这是一项 3b 期、扩大准入研究，评估了 ruxolitinib 在骨髓纤维化患者中的安全性和疗效，包括血小板计数低的患者。
Br J Haematol. 2020 Jun;189(5):888-903. doi: 10.1111/bjh.16462. Epub 2020 Feb 4.
4
Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.芦可替尼：一种新型 JAK1/2 抑制剂，为骨髓纤维化的治疗提供了有前景的选择。
Future Oncol. 2011 Sep;7(9):1035-43. doi: 10.2217/fon.11.81.
5
Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.鲁索替尼再激发可改善骨髓纤维化患者的全身症状和脾肿大：病例系列
Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e463-e468. doi: 10.1016/j.clml.2018.06.025. Epub 2018 Jun 28.
6
Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.鲁索替尼联合泼尼松治疗原发性骨髓纤维化患者期间发生致命播散性肺结核：一例报告及文献复习
Intern Med. 2018 May 1;57(9):1297-1300. doi: 10.2169/internalmedicine.9165-17. Epub 2017 Dec 27.
7
Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis.两名骨髓纤维化患者短暂停药后对鲁索替尼恢复反应
Am J Hematol. 2014 Mar;89(3):344-6. doi: 10.1002/ajh.23637.
8
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2032; author reply 2032-5. doi: 10.1056/NEJMc1203704.
9
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2031; author reply 2032-4. doi: 10.1056/NEJMc1203704.
10
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2031-2; author reply 2032-4. doi: 10.1056/NEJMc1203704.
引用本文的文献
1
Repurposing of Kinase Inhibitors for Treatment of COVID-19.激酶抑制剂在治疗 COVID-19 中的再利用。
Pharm Res. 2020 Aug 10;37(9):167. doi: 10.1007/s11095-020-02851-7.
2
Acute respiratory distress syndrome; A rare complication caused by usage of ruxolitinib.急性呼吸窘迫综合征；一种由芦可替尼使用引起的罕见并发症。
Respir Med Case Rep. 2017 Sep 18;22:243-245. doi: 10.1016/j.rmcr.2017.09.003. eCollection 2017.
本文引用的文献
1
Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.原发性骨髓纤维化：2013 年诊断、风险分层和治疗更新。
Am J Hematol. 2013 Feb;88(2):141-50. doi: 10.1002/ajh.23384.
2
Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.芦可替尼，一种口服 JAK1 和 JAK2 抑制剂，用于骨髓纤维化。
Expert Opin Pharmacother. 2012 Nov;13(16):2397-407. doi: 10.1517/14656566.2012.732998. Epub 2012 Oct 10.
3
Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.骨髓纤维化所致脾肿大——新的治疗选择和 Janus 激酶 2 抑制剂的治疗潜力。
J Hematol Oncol. 2012 Aug 1;5:43. doi: 10.1186/1756-8722-5-43.
4
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.芦可替尼治疗骨髓纤维化的双盲、安慰剂对照试验。
N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.
5
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.芦可替尼与最佳可用疗法治疗骨髓纤维化的 JAK 抑制作用比较。
N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.
6
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.费城阴性经典骨髓增殖性肿瘤：来自欧洲白血病网络的关键概念和管理建议。
J Clin Oncol. 2011 Feb 20;29(6):761-70. doi: 10.1200/JCO.2010.31.8436. Epub 2011 Jan 4.
7
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.基于骨髓纤维化研究与治疗国际工作组的一项研究的原发性骨髓纤维化新预后评分系统。
Blood. 2009 Mar 26;113(13):2895-901. doi: 10.1182/blood-2008-07-170449. Epub 2008 Nov 6.
8
Primary myelofibrosis: update on definition, pathogenesis, and treatment.原发性骨髓纤维化：定义、发病机制及治疗的最新进展
Annu Rev Med. 2009;60:233-45. doi: 10.1146/annurev.med.60.041707.160528.
9
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.JAK2在骨髓增殖性疾病发病机制及治疗中的作用。
Nat Rev Cancer. 2007 Sep;7(9):673-83. doi: 10.1038/nrc2210.
10
A gain-of-function mutation of JAK2 in myeloproliferative disorders.骨髓增殖性疾病中JAK2的功能获得性突变。
N Engl J Med. 2005 Apr 28;352(17):1779-90. doi: 10.1056/NEJMoa051113.
Zotero 插件